Consejo Superior De Investigaciones Científicas;Consorcio Centro de Investigación Biomédica en Red M.P.;Alianza Española De Familias De Von Hippel-Lindau -VHL
发明人:
申请号：
EP18382917.5
公开号：
EP3666266A1
申请日:
2018.12.12
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
The invention relates to the use of a selective β2 adrenergic receptor antagonist for treating glioma. In particular, the invention relates to the use of an alkanolamine derivative or a pharmaceutically acceptable acid-addition salt thereof for treating a glioblastoma in a patient.
